Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1252P - Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: Presentation of skin tumor data

Date

21 Oct 2023

Session

Poster session 14

Topics

Clinical Research;  Pathology/Molecular Biology;  Targeted Therapy

Tumour Site

Melanoma;  Basal Cell and Squamous Cell Cancers of the Skin

Presenters

Diederick Keizer

Citation

Annals of Oncology (2023) 34 (suppl_2): S711-S731. 10.1016/S0923-7534(23)01942-7

Authors

D. Keizer1, E. Niemela2, Y. Wesseling Rozendaal1, S. Karjalainen3, E. den Biezen1, A. Van Brussel1, M.V.J. Mustonen4, K. Peltola5

Author affiliations

  • 1 Oncosignal, InnoSIGN B.V, 5656 AE - Eindhoven/NL
  • 2 Deparment Of Genetic, Helsinki University Hospital, 00290 - Helsinki/FI
  • 3 Clinical Research, Helsinki University Hospital, 00290 - Helsinki/FI
  • 4 Fican South, Comprehensive Cancer Center - Helsinki University Central Hospital, 00029 - Helsinki/FI
  • 5 Clinical Trial Unit, Comprehensive Cancer Center - Helsinki University Central Hospital, 00029 - Helsinki/FI

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1252P

Background

Although genomic profiling is commonly used to characterize tumors, clinical treatment successes are limited. For many tumors no actionable results are found. Furthermore it is often unknown if an identified genomic alteration affects cell functionality. By using the OncoSIGNal platform technology the actual tumor-driving signal transduction pathway (STP) activities can be quantified resulting in unique tumor profiling. Using healthy tissue as reference, high pathway activities can be determined in an individual patient giving guidance for personalized treatment. Recently we demonstrated for breast and ovarian tumors this approach leading to highly personalized actionable results, which can be used in the FINPROVE study. We further expanded the approach to other tumors. Here the results of STP profiling of skin tumors are presented.

Methods

Using the mRNA-based OncoSIGNal pathway activity profiling PCR test (InnoSIGN), STP activities of 7 pathways (AR, ER, PI3K, MAPK, HH, TGFβ and Notch) in 25 samples from healthy skin tissue, 35 primary melanoma, 39 metastatic melanoma and 18 basal cell carcinoma (BCC) were quantified and expressed on a scale from 0-100. Only samples with ≥ 50% epithelial cell content were included. High pathway activity in a tumor sample was concluded when its score was higher than the 95th percentile of reference skin STP activity.

Results

Different profiles of high pathway activity were found across skin tumor types: Table: 1252P

HH MAPK PI3K TGFβ
BCC (n=18) 94% 44% 22% 11%
Primary melanoma (n=35) 14% 6% 51% 6%
Metastatic melanoma (n=39) 18% 15% 38% 5%

Further, within the skin tumor types, patient specific STP profiles were observed.

Conclusions

Using the OncoSIGNal test, actionable STP profiles were determined in samples from melanoma and BCC patients, creating opportunity for personalized targeted treatment. The OncoSIGNal test will be employed in the FINPROVE trial to identify patient specific actionable targets in several tumor types using tissue specific references.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

InnoSIGN.

Funding

Has not received any funding.

Disclosure

D. Keizer, E. den Biezen, A. Van Brussel: Financial Interests, Institutional, Full or part-time Employment: InnoSIGN. E. Niemela, S. Karjalainen: Financial Interests, Institutional, Full or part-time Employment: Helsinki University Hospital. Y. Wesseling Rozendaal: Financial Interests, Personal and Institutional, Full or part-time Employment, Full Time Employee: InnoSIGN. M.V.J. Mustonen: Financial Interests, Institutional, Full or part-time Employment: FICAN South, Helsinki University Hospital. K. Peltola: Financial Interests, Institutional, Full or part-time Employment: Comprehensive Cancer Center.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.